[{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"9e8100a2-7197-4a5c-9158-5afa688f8f49","acronym":"PANSOTO","url":"https://clinicaltrials.gov/study/NCT06892054","created_at":"2025-09-07T02:06:33.580Z","updated_at":"2025-09-07T02:06:33.580Z","phase":"Phase 2","brief_title":"Sotorasib Combined with First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT06892054 - PANSOTO","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-03-24"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"2155cc55-44be-403d-a3c7-183b3abe530b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638295","created_at":"2022-12-06T16:58:31.646Z","updated_at":"2025-02-25T12:29:13.134Z","phase":"Phase 2","brief_title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05638295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS","pipe":"","alterations":" ","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"84e74e03-8f34-4176-b63b-03c06eac53aa","acronym":"CodeBreaK 202","url":"https://clinicaltrials.gov/study/NCT05920356","created_at":"2023-06-27T14:08:07.537Z","updated_at":"2025-02-25T13:55:19.667Z","phase":"Phase 3","brief_title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","source_id_and_acronym":"NCT05920356 - CodeBreaK 202","lead_sponsor":"Amgen","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-02-20"},{"id":"8b904991-7019-4cce-9e04-2e7482447f70","acronym":"","url":"https://clinicaltrials.gov/study/NCT05815173","created_at":"2023-04-18T15:04:23.224Z","updated_at":"2025-02-25T14:09:36.744Z","phase":"Phase 1","brief_title":"Ladarixin With Sotorasib in Advanced NSCLC","source_id_and_acronym":"NCT05815173","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation","tags":["KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • ladarixin (DF-2156A)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-19"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"1bd93870-384f-4902-82c2-b2d46a884d55","acronym":"CodeBreak 100","url":"https://clinicaltrials.gov/study/NCT03600883","created_at":"2021-01-17T17:12:15.060Z","updated_at":"2025-02-25T16:31:27.902Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","source_id_and_acronym":"NCT03600883 - CodeBreak 100","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 713","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2025-02-07"},{"id":"713cf312-05ff-4ada-845c-c46ae3aa0c4a","acronym":"RAMP 203","url":"https://clinicaltrials.gov/study/NCT05074810","created_at":"2021-10-12T14:52:57.167Z","updated_at":"2025-02-25T16:53:53.800Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","source_id_and_acronym":"NCT05074810 - RAMP 203","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-04"},{"id":"26ce8992-3a8f-449a-80fd-e840f4035ed9","acronym":"AMBER","url":"https://clinicaltrials.gov/study/NCT06068153","created_at":"2023-10-05T16:11:10.857Z","updated_at":"2025-02-25T13:36:28.930Z","phase":"Phase 2","brief_title":"AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC","source_id_and_acronym":"NCT06068153 - AMBER","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Lumakras (sotorasib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-11-20"},{"id":"86dc5abc-d2d0-4384-ac0e-1203544bee99","acronym":"","url":"https://clinicaltrials.gov/study/NCT06582771","created_at":"2025-02-27T08:18:50.941Z","updated_at":"2025-02-27T08:18:50.941Z","phase":"Phase 2","brief_title":"A Study of Sotorasib in People with Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06582771","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/30/2024","start_date":" 08/30/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-12"},{"id":"7ae39bae-f74c-4bd9-bb9c-b0ac08141f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04892017","created_at":"2021-05-19T15:52:38.986Z","updated_at":"2024-07-02T16:34:26.607Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors","source_id_and_acronym":"NCT04892017","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KRAS • BRAF • NRAS • NF1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-13"},{"id":"b148efd6-3461-4443-b111-648b5d1400c0","acronym":"ECOG-ACRIN LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT04625647","created_at":"2021-01-19T20:35:28.296Z","updated_at":"2024-07-02T16:34:27.131Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT04625647 - ECOG-ACRIN LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12","tags":["EGFR • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 04/16/2021","start_date":" 04/16/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-11"},{"id":"67d0f4ee-9db1-45eb-830d-0ecad0fc8c25","acronym":"","url":"https://clinicaltrials.gov/study/NCT06249282","created_at":"2024-02-08T14:19:19.346Z","updated_at":"2024-07-02T16:34:59.110Z","phase":"Phase 1","brief_title":"Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06249282","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • carfilzomib"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 03/19/2026","primary_completion_date":" 03/19/2026","study_txt":" Completion: 03/19/2026","study_completion_date":" 03/19/2026","last_update_posted":"2024-06-04"},{"id":"36d108df-7220-49ba-9e5c-6bcdaeaf319d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04092673","created_at":"2021-01-18T20:01:41.284Z","updated_at":"2024-07-02T16:35:02.263Z","phase":"Phase 1/2","brief_title":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT04092673","lead_sponsor":"Effector Therapeutics","biomarkers":" KRAS • FGFR • CCND1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification","tags":["KRAS • FGFR • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Verzenio (abemaciclib) • Lumakras (sotorasib) • fulvestrant • zotatifin (eFT226)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"2d427c2c-44b2-4d75-9818-a28e1db0dc01","acronym":"CodeBreak 300","url":"https://clinicaltrials.gov/study/NCT05198934","created_at":"2022-01-20T15:53:54.576Z","updated_at":"2024-07-02T16:35:04.260Z","phase":"Phase 3","brief_title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","source_id_and_acronym":"NCT05198934 - CodeBreak 300","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 03/12/2025","primary_completion_date":" 03/12/2025","study_txt":" Completion: 03/12/2025","study_completion_date":" 03/12/2025","last_update_posted":"2024-05-13"},{"id":"a03cd0f9-38ee-421f-b425-e145989986da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05118854","created_at":"2021-11-12T13:53:36.072Z","updated_at":"2024-07-02T16:35:07.061Z","phase":"Phase 2","brief_title":"A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation","source_id_and_acronym":"NCT05118854","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Lumakras (sotorasib) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/30/2022","start_date":" 03/30/2022","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 10/20/2025","study_completion_date":" 10/20/2025","last_update_posted":"2024-04-29"},{"id":"5b0dcaae-cf24-41c0-a530-8101673f05e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05815186","created_at":"2023-04-18T15:04:23.494Z","updated_at":"2024-07-02T16:35:12.309Z","phase":"Phase 2","brief_title":"Ladarixin With Sotorasib in Advanced NSCLC - Phase II","source_id_and_acronym":"NCT05815186","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation","tags":["KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • ladarixin (DF-2156A)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-29"},{"id":"76fc1d25-302c-46d1-9853-e2d7d7bd994f","acronym":"CodeBreak 200","url":"https://clinicaltrials.gov/study/NCT04303780","created_at":"2021-01-17T17:12:15.501Z","updated_at":"2024-07-02T16:35:12.423Z","phase":"Phase 3","brief_title":"Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","source_id_and_acronym":"NCT04303780 - CodeBreak 200","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Lumakras (sotorasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 08/02/2022","primary_completion_date":" 08/02/2022","study_txt":" Completion: 04/27/2026","study_completion_date":" 04/27/2026","last_update_posted":"2024-03-28"},{"id":"9b81d62e-739f-42ad-9f9b-737dd9697422","acronym":"","url":"https://clinicaltrials.gov/study/NCT06333678","created_at":"2024-03-27T17:39:25.576Z","updated_at":"2024-07-02T16:35:12.566Z","phase":"Phase 2","brief_title":"A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06333678","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/20/2024","start_date":" 03/20/2024","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-03-27"},{"id":"c8f5cf1c-74ec-40d3-82b6-7b8da7d353a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04380753","created_at":"2021-01-18T21:09:24.431Z","updated_at":"2024-07-02T16:35:13.108Z","phase":"Phase 1","brief_title":"AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).","source_id_and_acronym":"NCT04380753","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/28/2020","start_date":" 04/28/2020","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-03-22"},{"id":"d64a4376-f3c6-468c-8bab-9e4a850eabdc","acronym":"Argonaut","url":"https://clinicaltrials.gov/study/NCT05480865","created_at":"2022-07-29T15:55:28.505Z","updated_at":"2024-07-02T16:35:21.318Z","phase":"Phase 1","brief_title":"SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation","source_id_and_acronym":"NCT05480865 - Argonaut","lead_sponsor":"Navire Pharma Inc., a BridgeBio company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • BMS-986466"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-01"},{"id":"7a1cb5a1-d7f1-42a2-82f2-93348d1b651b","acronym":"SOLUCOM","url":"https://clinicaltrials.gov/study/NCT05311709","created_at":"2022-04-05T13:52:38.382Z","updated_at":"2024-07-02T16:35:29.731Z","phase":"Phase 2","brief_title":"Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities","source_id_and_acronym":"NCT05311709 - SOLUCOM","lead_sponsor":"Vestre Viken Hospital Trust","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-11-09"}]